Imunon, INC 8-K filings

Imunon, Inc. appoints Dr. Douglas V. Faller as Chief Medical Officer to lead clinical strategy, including the Phase 3 pivotal trial of IMNN-001 for advanced ovarian cancer.

Imunon, Inc. has received a notification from Nasdaq that its stock price has fallen below the minimum $1.00 per share requirement for continued listing.

Imunon announced positive Phase 2 clinical trial results for its lead drug candidate, IMNN-001, showing significant survival improvements in advanced ovarian cancer patients, and reported its third quarter 2024 financial results.

Imunon, Inc. has appointed Susan Eylward as General Counsel and Corporate Secretary, granting her inducement stock options as part of her employment agreement.

Imunon, Inc. has resumed its at-the-market offering of common stock after a temporary suspension, filing a new prospectus supplement and legal opinion.

Imunon announced positive topline results from its Phase 2 OVATION 2 study for advanced ovarian cancer, showing a significant increase in overall survival, and secured $10 million in a registered direct offering.

Imunon, Inc. has announced a registered direct offering of 5 million shares of its common stock.

Imunon, a clinical-stage biotech company, has entered into agreements for a $10 million registered direct offering of its common stock and warrants.

Imunon's Phase 2 OVATION 2 trial of IMNN-001 in combination with chemotherapy shows a significant increase in overall survival for patients with advanced ovarian cancer.

Imunon, Inc. held its 2024 Annual Meeting of Stockholders on June 12, 2024, where directors were elected, the appointment of an independent auditor was ratified, and executive compensation was approved on an advisory basis.

Imunon, Inc. has announced the retirement of its Chief Financial Officer, Jeffrey Church, and the appointment of David Gaiero as his successor, effective June 1, 2024.

Imunon announced its first quarter 2024 financial results, provided updates on its clinical programs, and appointed a new CEO.

Imunon, Inc. has appointed Stacy R. Lindborg, Ph.D., as its new President and Chief Executive Officer, effective May 13, 2024, bringing extensive experience in drug development and executive leadership.

Imunon, Inc. has regained compliance with Nasdaq's minimum bid price requirement after its stock price exceeded $1.00 for ten consecutive trading days.

Imunon reported encouraging interim clinical trial results for its ovarian cancer treatment and progress in its vaccine platform, alongside its 2023 financial results.

Imunon, Inc. has updated its bylaws to align with recent changes in Delaware General Corporation Law, affecting voting thresholds and meeting adjournment procedures.

Imunon, Inc. announces the resignation of its CEO, Dr. Corinne Le Goff, effective March 15, 2024, with the Executive Chairman assuming day-to-day leadership while a search for a successor is conducted.